Tirzepatide for Obesity and Meth Use Disorder
NCT06745128 on ClinicalTrials.gov · last registry update 2026-09-28
A small phase 2 — 35 participants, against a typical 110. The sponsor logged completion for 12 February 2026. Primary outcome, as filed: Effect of tirzepatide on self-reported use of methamphetamine. tirzepatide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 3 times since then.
- Status
- COMPLETED
- Phase
- P2
- Drug
- tirzepatideMounjaro, Zepbound
- Sponsor
- University of Texas Southwestern Medical Center
- Sponsor type
- Other
- Enrollment
- 35
- Started
- 2025-02-03
- Primary completion
- 2026-02-12 actual
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-28 | Status changed | ACTIVE_NOT_RECRUITING → COMPLETED |
| 2026-09-28 | Reporting date moved | 2026-03-31 → 2026-02-12 1 months earlier |
| 2026-09-28 | Enrollment changed | 45 → 35 (-10) participants |
Primary outcome
Effect of tirzepatide on self-reported use of methamphetamine
Conditions studied
Obesity · Methamphetamine Use Disorder
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.